BioSpace News Archive

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, announced today that it has entered into a securities purchase agreement with several institutional investors in the United States providing for the sale and issuance of approximately 12,427,876 common shares at a purchase price of $0.56325 per common share in a register

PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a research collaboration with Wuxi Shuangliang Biotechnology (SLBio) to evaluate the combination of each party’s clinical candidate, olinvacimab and C-005, a 3 rd generation of EGFR inhibitor with superior brain-blood-barrier permeability, in treating non-small cell lung cance

Premier Research continues to build its oncology expertise with the addition of Cassandra Matney, M.D., as Senior Medical Director.

More than 40 percent of coronavirus deaths in the U.S. linked to long-term care facilities; urgent need for therapeutic strategies to prevent COVID-19 in this vulnerable population

Accomplished leader with proven record of achievement to drive next phase of Company’s growth

Precision BioSciences, Inc., a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform announced it will report financial results for the second quarter of 2020 on August 13, 2020.

GranBio, a 100% Brazilian industrial biotechnology company, and NextChem, Maire Tecnimont’s subsidiary for energy transition announced a strategic partnership to achieve global leadership in the licensing of patented GranBio 2G Ethanol technology to produce cellulosic ethanol.

GTCR, a leading private equity firm, announced that its TerSera Therapeutics LLC portfolio company has entered into a definitive agreement to acquire the product Xermelo® from Lexicon Pharmaceuticals, Inc. for an upfront purchase price of approximately $159 million plus potential milestone payments based on development and commercialization of Xermelo in a new indication.

Graybug Vision, Inc. announced the appointment of leading ophthalmologists and retinal experts to provide external scientific counsel on the company’s research and development programs.

AbCellera Provides COVID-19 Program Update with the Start of Phase 3 Clinical Trials and the Expansion of its COVID-19 Antibody Database As LY-CoV555 advances into Phase 3 COVID-19 prevention studies, AbCellera’s COVID-19 database reaches over 2,000 new antibodies against the virus, discovered from recovered patient samples